Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2025.12.03.692062

Resolving the CES1 Genomic Locus with Cas9-Directed Targeted Long-Read Sequencing for Precision Pharmacogenomics

Lekka, E.·Ambrodji, A.·Nater, A.·Ballah, A.·Amstutz, U.·Ramette, A.·Largiader, C. R.
View original source ↗Export metadata ↓

Abstract

Carboxylesterase 1 (CES1) is the primary hepatic hydrolase in humans, crucial for the metabolism of ester-containing drugs and endogenous lipids. However, the CES1 genomic region is difficult to resolve because of adjacent highly homologous pseudogenes and the presence of large structural variants. These complexities often cause read misalignment and inaccurate variant calling with conventional short-read sequencing, hindering reliable pharmacogenomic analyses. To overcome these limitations, we employed an optimized, PCR-free Oxford Nanopore Technologies (ONT) sequencing method, Cas9directed targeted sequencing (nCATS), to characterize the targeted region of up to 76 kb, including CES1, CES1P1 or CES1A2, and their intergenic regions. This approach uses Cas9 to selectively enrich and sequence long native DNA fragments, while avoiding amplification-induced artefacts. Long-read sequencing was performed in 23 human blood samples and the HepG2 hepatoblastoma cell line enabling high-resolution mapping to the CES1 locus. We uncover five previously unrecognized main CES1 haplotypes and report that many single nucleotide variants (SNVs) in public databases are likely artefacts caused by short-read misalignment. Additionally, we identify long inverted repeats (LIRs) flanking a fragile genomic site within the region, which may form DNA hairpins and contribute to structural plasticity at the locus. This study demonstrates the utility of long-read sequencing for resolving complex genomic regions such as CES1, allowing comprehensive detection of structural variants and haplotype-resolved SNVs. Our findings provide improved reference sequences and deeper insight into CES1 diversity, with significant implications for future pharmacogenetic research and the development of personalized treatment strategies involving CES1-metabolized medications.

Explore related subjects

geneticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lekka, E., Ambrodji, A., Nater, A., Ballah, A., Amstutz, U., Ramette, A., Largiader, C. R.. 2025-12-05. Resolving the CES1 Genomic Locus with Cas9-Directed Targeted Long-Read Sequencing for Precision Pharmacogenomics. https://doi.org/10.64898/2025.12.03.692062

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗
bioRxiv2026

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗
bioRxiv2026

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗